Trial Profile
A prospective study assessing hepatic disorders associated with teriflunomide treatment in patients with multiple sclerosis.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2016
Price :
$35
*
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
- 26 Feb 2016 New trial record